arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

BIOTRICITY INC.

BTCY
— Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
54 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Bearish
auto_awesome

Analytical Summary

BIOTRICITY INC. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 10.4% ↘
Op. Margin 3.7% ↘
ROIC -0.4% ↗
FCF / Share $0.02
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.28M
↑ +10.4% —
Net Income Profit after all expenses
$-959.47K
↓ -42.8% —
Operating Margin Operating profit as % of sales
3.7%
↓ -77.4% 66th
FCF / Share Free cash flow per share
$0.02
↑ +181.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
28
Returns ↓
56
Financial Health
49
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 54 quarters